Gilnature/iStock via Getty Images My previous coverage on Ardelyx (NASDAQ:ARDX), now a $2 billion cap biopharmaceutical, came during FDA approval of tenapanor’s second indication. The first and only phosphate absorption inhibitor is now sold as XPHOZAH in combination with phosphate binders to treat hyperphosphatemia in adults with end-stage renal disease (ESRD) on dialysis, as well as IBSRELA for irritable bowel syndrome with constipation. Since publication, shares skyrocketed more than 230% as the comp ...